A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors

• Published in: Anti-cancer drugs Vol. 35; no. 5; p. 450
• Main Authors: Poklepovic, Andrew S, Gordon, Sarah W, Kothadia, Sejal, McGuire, William P, Thacker, Leroy R, Deng, Xiaoyan, Tombes, Mary Beth, Shrader, Ellen, Hudson, Daniel, Bandyopadhyay, Dipankar, Ryan, Alison A, Kmieciak, Maciej, Smith, Steven, Dent, Paul
• Format: Journal Article
• Language: English
• Published: England 01.06.2024
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Genital Neoplasms, Female - chemically induced; Genital Neoplasms, Female - drug therapy; Humans; Maximum Tolerated Dose; Neoplasms - drug therapy; Neoplasms - pathology; Phenylurea Compounds - adverse effects; Pyridines - therapeutic use; Sildenafil Citrate - adverse effects
• ISSN: 1473-5741
• DOI: 10.1097/CAD.0000000000001584

The purpose of this study is to establish the recommended phase 2 dose for regorafenib in combination with sildenafil for patients with advanced solid tumors. Secondary outcomes included identification of antitumor effects of regorafenib and sildenafil, toxicity of the combination, determination of PDE5 expression in tumor samples, and the impact of sildenafil on the pharmacokinetics of regorafenib. This study was a phase 1, open-label single-arm dose-escalation trial using a 3 + 3 design. Additional patients were enrolled at the maximum tolerated dose (MTD) until a total of 12 patients were treated at the MTD. A total of 29 patients were treated in this study. The median duration of treatment was 8 weeks. The recommended phase 2 doses determined in this study are regorafenib 160 mg daily with sildenafil 100 mg daily. The most common toxicities included palmar-plantar erythrodysesthesia syndrome (20 patients, 69%) and hypophosphatemia (18 patients, 62%). Two patients (7%) experienced grade 4 lipase increase. Objective responses were not observed; however, 14 patients (48%) had a period of stable disease during the study. Stable disease for up to 12 months was observed in patients with ovarian cancer as well as up to 20 months for a patient with cervical cancer. The combination of regorafenib and sildenafil at the recommended phase 2 dose is safe and generally well tolerated. Disease control in patients with gynecologic malignancies was especially encouraging. Further evaluation of the combination of regorafenib and sildenafil in gynecologic malignancies is warranted. Clinical Trial Registration Number: NCT02466802.